+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hepatorenal Drug"

Hepatorenal Syndrome Treatment Market by Product Type (Branded, Generic), Route Of Administration (Intravenous, Oral), Patient Severity, End User - Global Forecast 2025-2030 - Product Thumbnail Image

Hepatorenal Syndrome Treatment Market by Product Type (Branded, Generic), Route Of Administration (Intravenous, Oral), Patient Severity, End User - Global Forecast 2025-2030

  • Report
  • August 2025
  • 180 Pages
  • Global
From
Hepatorenal Syndrome Treatment Market Report 2025 - Product Thumbnail Image

Hepatorenal Syndrome Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Hepatorenal Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatorenal Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hepatorenal Syndrome (HRS) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hepatorenal Syndrome (HRS) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

The Hepatorenal Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. It focuses on drugs used to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including cirrhosis, hepatitis, nephrotic syndrome, and renal failure. They can also be used to reduce the risk of complications from liver and kidney diseases. Common drugs in this market include antivirals, immunosuppressants, diuretics, and antifibrotics. The Hepatorenal Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in this market include AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, and Pfizer. Other companies include AstraZeneca, Bayer, Novartis, and Sanofi. Show Less Read more